title: Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.
abstract: We used Surveillance, Epidemiology, and End Results-Medicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HR] 0.54; 95% Confidence Interval [CI] 0.39-0.74; p < .001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.
authors.affiliation: Outcomes Insights, Inc., Westlake Village, CA 91362, USA. bob@outins.com
authors.forename: Robert I
authors.initials: RI
authors.lastname: Griffiths
authors.forename: Deepa
authors.initials: D
authors.lastname: Lalla
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Herbert
authors.forename: Justin F
authors.initials: JF
authors.lastname: Doan
authors.forename: Melissa G
authors.initials: MG
authors.lastname: Brammer
authors.forename: Mark D
authors.initials: MD
authors.lastname: Danese
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D009362:Neoplasm Metastasis; D018426:SEER Program; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D043823:Taxoids; D000068878:Trastuzumab